Integrated Protocol /Study number BAY 63 -2521/12935/ Page 1of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Bayer
CLINICAL STUDY PROTO COL
Title:Long -term extension, multi -centre , multi -national study  
to evaluate the safet y and tolerability of oral 
BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in 
patients with sy mptomatic Pulmonary  Arterial 
Hypertension (PAH) .PATENT -2Study
Test Drug: BAY 63-2521 (INN Riociguat)
Sponsor’s Name and Address: Bayer HealthCare AG
D-51368 Leverkusen
Study Number/Version/Date: 12935/ Version 2.0/ 200 8-Sep-11
The following Amendments have been incorporated into this Integrated Protocol.
AMENDMENT 
NUMBERVERSION NUMBER DATE
Amendment 5 1.0 10-June-2009
Amendment 6 1.0 22-March -2010
Amendment 8 1.0 15-Feb-2011
Amendment 11 1.0 13-Dec-2012
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 2of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Table of Contents
Table of Contents ................................ ................................ ................................ ....................... 2
Glossary  and Abbreviations ................................ ................................ ................................ .......4
1.INTRODUCTION ................................ ................................ ................................ .............. 6
2.STUDY OBJECTIVES ................................ ................................ ................................ ......7
3.INVESTIGATOR(S) AND OTHER STUDY PARTI CIPANTS ................................ ......7
4.INVESTIGAT IONAL PLAN ................................ ................................ ............................ 8
4.1 Study  Design and Plan ................................ ................................ ................................ 8
4.2 Selection of Study  Population ................................ ................................ ................... 13
4.2.1 Inclusion Criteria ................................ ................................ ............................... 13
4.2.2 Exclusion Criteria ................................ ................................ .............................. 13
4.3 Removal of Patients from Study ................................ ................................ ............... 14
4.4 Premature Termination of Study /Closure of Centre ................................ ................. 15
4.5 Treatments ................................ ................................ ................................ ................. 16
4.5.1 Treatments to be ad ministered ................................ ................................ ........... 16
4.5.2 Identity  of Investigational Product(s) ................................ ................................ 16
4.5.3 Method of Assigning Patients to Treatment Groups ................................ .......... 17
4.5.4 Selection of Doses in the Study ................................ ................................ ......... 17
4.5.5 Selection and Timing of Dose for Each Patient ................................ ................. 17
4.5.6 Blinding ................................ ................................ ................................ .............. 18
4.5.7 Concomitant Therap y................................ ................................ ......................... 18
4.5.8 Treatment Compliance ................................ ................................ ....................... 21
4.6 Study  Variables ................................ ................................ ................................ ......... 21
4.6.1 Safety  Variables ................................ ................................ ................................ .21
4.6.2 Other Variables ................................ ................................ ................................ ..22
4.6.3 Assessment Periods ................................ ................................ ............................ 22
4.6.4 Observations and Measurements ................................ ................................ .......30
4.6.5 Drug Con centration Measurements ................................ ................................ ...37
4.7 Data Qualit y................................ ................................ ................................ .............. 38
4.8 Documentation ................................ ................................ ................................ .......... 38
5.ETHI CAL  AND LEGAL ASPECTS ................................ ................................ ............... 39
5.1 Ethics Committee (EC) or Institutional Review Board (IRB) ................................ ..39
5.2 Ethical Conduct of the Study ................................ ................................ .................... 39
5.3 Regulatory  Authority  Approvals/Authorizations ................................ ...................... 40
5.4 Patient I nformation and Consent ................................ ................................ ............... 40
5.5 Insurance ................................ ................................ ................................ ................... 40
5.6 Confidentiality ................................ ................................ ................................ ........... 40
6.STATI STICAL METHODS AND DETERMINATION OF SAMPL E SIZE................ 41
6.1 Statistical and Analy tical Plans ................................ ................................ ................. 41
6.2 Determination of Sample Size ................................ ................................ ................... 42
7.ADVERSE EVENTS ................................ ................................ ................................ .......43
7.1 Contraindications/Warnings/Precautions/I nteractions/Undesirable Effects ............. 43
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 3of 75
Final Version 1.0/ 13 Dec 2012/AM D 117.2 Adve rse Event Monitoring ................................ ................................ ........................ 46
7.3 Adverse Event Definitions ................................ ................................ ........................ 46
7.3.1 Adverse Event ................................ ................................ ................................ ....46
7.3.2 Serious Adverse Event ................................ ................................ ....................... 47
7.3.3 Unexpected Adverse Event ................................ ................................ ................ 49
7.3.4 Relationship of Adverse Event to I nvestig ational Product ................................ 49
7.3.5 Severity  of the Adverse Event ................................ ................................ ........... 50
7.3.6 Adverse Event Documentation ................................ ................................ .......... 51
7.4 Reporting of Serious Adverse Events/Pregnancy ................................ ..................... 51
7.5 Reporting of Safet y Related Events of Special Interest ................................ ............ 52
8.USE OF DATA AND PUBLICATION ................................ ................................ ........... 52
9.REFERENCES ................................ ................................ ................................ ................. 53
10. APPENDI CES ................................ ................................ ................................ .............. 53
10.1 Study  Flow Chart ................................ ................................ ................................ ......54
10.2 Pharmacokinetic Sampling ................................ ................................ ........................ 61
10.3 Blood Gas Analy sis................................ ................................ ................................ ...61
10.4 6 Min Walking Distance (6MWD) Test ................................ ................................ ....62
10.5 Borg CR 10 Scale®or Modified Borg Dy spnoea Scale ................................ ............ 64
10.5.1 Borg CR 10 scale and test instructions ................................ .............................. 64
10.5.2 Modified Borg Dy spnoea Scale ................................ ................................ ......... 66
10.6 WHO functional cla ss................................ ................................ ............................... 67
10.7 EQ-5D................................ ................................ ................................ ....................... 67
10.8 Living with Pulmonary  Hypertension questionnaire (L PH)................................ .....72
10.9 Role of the Steering Committee (SC) ................................ ................................ .......74
10.10 Role of the Data Monitoring Committee (DMC) ................................ .................. 74
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 4of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Glossary and Abbr eviations
6MW D 6-minute w alking distance
AE adverse event or experience
ALT alanine aminotransferase (also known as SGPT, qv)
ALP alkaline phosphatase
AST aspartate aminotransferase (also known as SGOT, qv)
CCW concalc for Windows
cGMP cyclic guanosine monophosphate
CHE Cholinesterase
CK creatine kinase
CRF case report form
eCRF electronic case report form
CT computed tomograph y
CTEPH chronic thromboembolic pulmonary  hypertension
CYP3A4 cytochrome P450 isoenzy me 3A4 (etc)
d Day
EC ethical committee
ECG Electrocardio gram
eg exempli gratia , for example
EQ-5D EuroQol questionnaire
g standard acceleration due to gravit yat the Earth's surface, by  
definition: g= 9.80665 m/sec2
GCP Good Clinical Practice
GGT gamma glutam yl transpeptidase
GLDH glutamate deh ydrogenase
h Hour
H Height
HDPE High Density  Polyethylen
HEOR Health Economics, Outcomes and Reimbursement
HPLC high pressure liquid chromatograph y
ie id est, that is
IR immediate release
INR international normalized ratio (prothrombin time expressed in 
relation to normal value)
IRB Institutional Review Board
iv Intravenous
IVR / IVRS interactive voice respon sesystem
LPH Living with Pulmonary  Hypertension q uestionnaire
M-1 metabolite M -1
mg Milligram
mmHg millimeter of mercury
MRR Medical Research Re port
NO Nitric oxide
NT-proBNP N-terminal pro -brain natriuretic peptide
O2 Oxygen
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 5of 75
Final Version 1.0/ 13 Dec 2012/AM D 11PaCO 2 arterial partial pressure of carbon dioxide
PaO2 arterial partial ox ygen pressure
PEA Pulmonary  endarterectomy
PDE5 phosphodiesterase t ype-5
PH pulmonary  hypertension
PK Pharmacokinetic
PTT partial thromboplastin time
PvO2 venous ox ygen pressure
PVOD Pulmonary -veno -occlusive disease
QC quality  control
SAE serious adverse event
SaO2 oxygen saturation
SAS Statistical Analy sis Sy stem
SBP systolic blood pres sure
tid ter in die (3 times a day )
WHO World Health Organization
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 6of 75
Final Version 1.0/ 13 Dec 2012/AM D 111.INTRODUCTION
Please see INTRODUCTION of the BAY 12394 (PATENT -1) protocol.
In addition, the following aspects should be considered with respect to the long -
term extension trial:
Based on the currently  available scientific evidence, a large proportion of 
Pulmonary  Artery  Hypertension (PAH) patients cannot be cured. Therefore, it can 
be assumed that their disease will progress over the years, requiring a long -term 
medical treatment to maintain their quality  of life and to increase their life 
expectancy .
Although the experiences with BAY 63-2521 with respect to the treatment of PAH 
are limited, in the light of the severit y of the underlying disease it isjustified to offer 
all patient swho participated in the PATENT -1 trial a long-term treatment with 
BAY 63-2521 (until commerciall y available).
In this context, it should be highlight edthat BAY 63-2521 revealed a positive 
benefit -risk ratio in the trials conducted in Pulmonary  Hypertension (P H) patients to 
date (trials # 11874 and #12166), allowing continuation of the development 
program. Moreover, in a first interim analysis of the extension phase of trial # 
12166 (includes 21 patient s with a BAY 63-2521 treatment up to one year) the 
improve ments in walking distance observed within the first 12 weeks of treatment 
were sustained without any  significant safet y concerns.
For further information refer to the Investigator Brochure. The Investigator’s 
Brochure will be updated at regular intervals during the conduct of the trial. New 
versions of the Investigator’s Brochure will be made available to the investigators 
without delay
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 7of 75
Final Version 1.0/ 13 Dec 2012/AM D 112.STUDY  OBJECTIVES
To assess the long-term safet y and tolerability  of BAY 63-2521 in treatment naive 
patients and patients pretreated with an Endothelin Receptor Antagonist or a 
Prostacy cline Analogue with sy mptomatic Pulmonary  Arterial Hy pertension (PAH).
The trial provides patients, who have completed 12weeks of BAY 63-2521 double 
blind treatment (PATENT -1 trial, #12934 ), the option of long-term treatment with 
BAY 63-2521.
Efficacy  assessments are included to provide an indication of maintenance of 
efficacy  with long -term treatment.
3.INVESTIGA TOR(S) AND OTHER STUDY  PARTICIP ANTS
Principal Investigator/Coordinating Investigato r of the study
Name:
Address:
The Study  Manager and the Medical Expert will appoint the coordinating 
investigator responsible for signing the MRR.
Information regarding additional key  personnel involved in the conduct of the study , 
including names and contact details of participating investigators, monitors, clinical 
laboratories, technical departments and/o r institutions, as well as information on 
members of additional study  committees, will be found in the study  files of the 
sponsor and on site if requested.
PPD
PPD
PPD
PPD
PPD
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 8of 75
Final Version 1.0/ 13 Dec 2012/AM D 114.INVESTIGA TIONAL  PLAN
4.1 Study Design and Plan
Multi centre , multinational, open label one arm study  inpatients with symptomatic 
PAH .
Study Phases:
 Treatment Phase:
Titration Phase: 8 weeks
Main -Study  Phase: Duration until BAY 63-2521 receives official 
approval and will be commerciall y available
 Safety  Follow Up Phase: 30 day s
BAY 63-2521 will be administe red orally  as a tablet in doses of 0.5 mg, 1.0mg, 1.5
mg, 2.0 mg, and 2.5 mg tid.
Titration Phase (8 weeks):
General aspects:
During the first eight weeks of the trial, patients from the Placebo Arm and from the 
BAY 63-2521 1.5 mg Dose Arm (applies only to patients who reached the 1.5 mg 
tid level) of PATENT -1 trial will be up-titrated , if tolerated, up to 2.5 mg 
BAY 63-2521 tidaccording toan individual dose titration scheme .
To maintain the blinding of PATENT -1,the PATENT -2 study  medication 
(BAY 63-2521) is blinded with respect to the dose during the Titration Phase and
investigator swillnot know at which dose level a certain patient enters the
PATENT -2 trial.
Patients from the BAY 63-2521 Individual Dose Titration Arm and the 
BAY 63-2521 1.5 mg Dose Arm will enter the extension trial on the same dose level 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 9of 75
Final Version 1.0/ 13 Dec 2012/AM D 11which they have received on the last day of PATENT -1, while patients from the 
Placebo Arm will start at Visit 1 with a BAY 63-2521 dose of 1.0 mg tid.
To allow ablinded individual dose titration , the titration will be performed with the 
aid of an IVR-System. At each Titration Visit (with the exception of Visit 1)the 
investigator need sto decide, based on the patient’s systolic blood pressure, if the 
study  medication dose should be modified. The respective decision (increase, 
maintain or decrease dose) must be entered in the IVR-System that will 
automatically  allocate the right dose in accordance with the respective titration 
scheme. Afterwards, the investigator will be informed by the system, which of the 
blinded medication bottles (blinded with respect to the dose) needs to be hand ed
over for the next titration period (starts alway s with the morning dose).
Independentl y from the patient’s allocation to a specific treatment arm in
PATENT -1, the inves tigators will appl y the following blood pressure based titration 
rules for their dose decision in PATENT -2:
The individual study  medication dose of the next titration step will be 
determined every  2 weeks according to the peripheral SBP measured at trough 
before intake of the morning dose under consideration of the following 
algorithm (= individual dose titration scheme):
If trough SBP 95 mmHg ,increase dose (+0.5 mg tid) .
If trough SBP 90 -94 mmHg, maintain dose .
If trough SBP <90 mmHg without symptoms of hypotension ,reduce dose (-
0.5 mg tid) .
If any SBP <90 mmHg with clinical symptoms of hypotension such as 
dizziness or presyncope, stop study  treatment; restart after 24 hours with 
reduced dose ( -0.5 mg tid).
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 10of 75
Final Version 1.0/ 13 Dec 2012/AM D 11In general, if the investigator requests an increase or decrease of study  medication 
dose via the IVR-System, the subsequent dose modification will not exceed 
plus/minus 0.5 mg study  medication.
Although the individual dose titration scheme is solely  based on the patient’s 
systolic blood pressure, investigators are obliged to consider in addition the 
patient’s well being. Therefore, it is allowed in case of study  medication side 
effects, to suspend a foreseen up -titration step and to maintain the dose.
To request an increase of study  medication dose is only possible at the planned 
study  visits Visit 2, Visit 3 and Visit 4.
The Titration Phase ends at day 56 (Visit 5). At this visit theactual dose of the 
patients will be unblinded by  the IVR-System .
Patients from the PATENT -1 Placebo Arm:
For patients from the PATENT -1 Placebo Arm the starting dose will be 1 mg 
BAY 63-2521 tid. The individual BAY 63-2521 dose will be titrated every 2 weeks 
according to the peripheral SBP measured at trough before intake of thenext
morning dose. At the end of the Titrat ion Phase (Visit 5) patients will have reach ed 
BAY 63-2521 dose sbetween 0.5 mg tid and 2.5 mg tid .
2 weeks2 weeks2 weeks2 weeks 2.0mg tid
1.5mg tid
1mg tid
V2 V1V3V4V5 Vn
Vn
Vn
Vn
Vn0.5 mg tid1.5mg tid
1.0mg tid2.0mg tid2.5mg tid 2.5 mg tid
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 11of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Patients from the PATENT -1 1.5 mg Dose Arm:
Patients from the PATENT -1 1.5 mg Dose Arm will enter the extension trial on the 
same dose which they  have received on the last day  of PATENT -1 (Visit 6).
 In case that starting dose of PATENT -2 is 1.5 mg tid, the individual optimal 
BAY 63-2521 dose will be determined every 2 weeks according to the 
peripheral SBP measured at trough before intake of the next morning dose. At 
the end of the Titration Phase (Visit 5) respective patients will have reached 
BAY 63-2521 doses between 0.5 mg tid and 2.5 mg tid.
 In case that starting dose of PATENT -2 is 1.0 mg tid or 0.5 mg tid, the dose
cannot be further increased until Visit 5. If the investigator requests a dose 
increase above that level via the IVR-System, the patient will undergo a sham 
titration. Nevertheless, in case that the investigator requests a dose decrease 
(eg for safety  reason), dose modifications are possible (i.e. from 1.0 mg tid to 
0.5 mg tid), but without a subsequent re-increase before Visit 5.Patients who 
do not tolerate the lowest BAY 63-2521 (0.5 mg tid) must be withdrawn from 
the trial (see section 4.3)
Patients from the PATENT -1 Individual Dose Titration Arm:
Patients from the BAY 63-2521 Individual Dose Titration Arm of thePATENT -1 
study  will enter the extension trial on the same dose which they  have received on the 
last day of PATEN T-1(Visit 6).Although the investigator will apply during the 2 weeks2 weeks2 weeks 2 weeks
1.5 mgtid
V5 Vn
Vn
Vn
Vn
Vn0.5 mg tid1.5mg tid
1.0mg tid2.0mg tid2.5mg tid 2.5 mg tid
V1 V2V32.0mg tidV4
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 12of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Titration phase the same titration rules as for the PATENT -1 placebo patients , the 
individual dose cannot be increased above the dose received at last day  of
PATENT -1.If the investigator reque sts a dose increase above th at level via the IVR -
System, the patient will undergo a sham titration. Nevertheless, in case that the 
investigator requests a dose decrease (eg for safety  reason) , dose modifications are
possible , but without a subsequent re -increase before Visit 5 .
Main -Study Phase (Duration until BAY 63-2521 receives official approval and 
will be commercially available ):
From Visit 5 on (begin of the Main -Study  Phase)investigators are allowed to 
modify  the BAY 63-2521 dose in a dose range between 0.5 mg tid and 2.5 mg tid
according to the patient ’s need. In contrast to the Titration Phase, patients may be 
up-titrated between regular schedule dvisits. In this context, investigators have to 
consider the patient’s blood pressure (refer to the individual dose titration scheme) , 
potential BAY 63-2521 side effects and the progression of the underly ing
Pulmonary  Hypertension .
Safety Follow Up Phase (30days)
For all patients stopping study  treatment at any time aSafety Follow Up Visit 30 
days after s top of study  medication intake should be performed.
General Note : Stop of study  medication and dose reductions for safet y reasons (eg 
patient suffers from severe symptomatic hypotension) are allowed at anypoint in 
time during the Titration and the Main -Study Phase. In case of intended dose 
reductions the investigator will contact the IVR-System, which can be done 
independentl y from any planned study  visit, and request a dose reduction (-0.5 mg 
study  medication).
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 13of 75
Final Version 1.0/ 13 Dec 2012/AM D 114.2 Selection of Study Population
4.2.1 Inclusion Criteria
Patients who have completed 12weeks of treatment in the double blind trial 
PATENT -1.
Patients must have given their written informed consent to participate in the 
study  after having received adequate previous information and prior to any 
study -specific procedures.
4.2.2 Exclusion Criteria
Patient’s participating in another clinical trial 
Patients who have an ongoing serious adverse event from PATENT -1 that is 
assessed as related to BAY 63-2521 are not allowed toparticipate in the 
extension trial .
Pregnant women (i.e. positive serum ß-human -chorionic -gonadotropin test or 
other signs of pregnancy) or breast feeding women, or women with childbearing 
potential not using a combination of safe contraception method s.
Patients with a medical disorder, condition, or history  of such that would impair 
the patient's ability  to participate or complete this study  in the opinion of the 
investigator or the sponsor.
Pertinent non compliance with the conditions for the trial or instructions by the 
invest igator during PATENT -1 participation.
Patients with hypersensitivity  to the investigational drug or inactive 
constituents.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 14of 75
Final Version 1.0/ 13 Dec 2012/AM D 114.3 Removal of Patient s from Study
A patient who withdraws is one who discontinued in a clinical study  for any reason.
Patients may  be withdrawn from the study  for the following reasons:
At their own request .
At the specific request of the sponsor ( egdetection of a new significant 
safet y concern related to the study drug) .
Occurrence of adverse events or intercurrent diseases which the investigator 
judges unacceptable for continuation of participation in the study .
Occurrence of adverse drug reactions, which have from the investigator’s 
point of view, a negative impact on the patient’s individual Risk -Benefit 
Ratio (I nvestigators are obliged to reassess the patient’s individual Risk -
Benefit Ratio on a continuous basis. Factors like anticipated treatment effect, 
progression of underly ing disease, occurrence of side effects and alternative 
treatment options have to be considered) .
Pertinent non -compliance with the conditions for the trial or instructions by  
the investigator
Although not intended, patients m ay interrupt their intake of study  
medication due to various reasons (eg hospitalization in a remote hospital 
without study  medication access, safet y reasons, side effects ).
-In case that a ninterruption took place during the Titration Phase and lasts 
longer than 3 day s at a stretch (9 missing doses), it is not allowed to restart 
the study  medication again (respective patients must be withdrawn from the 
trial). In case of shorter interruptions, it is at the discretion of the investigator 
if the study  medic ation can be restarted.
-In case that a ninterruption took place during the Main Study  Phase and lasts 
longer than 14 day s at a stretch, it is not allowed to restart the study  
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 15of 75
Final Version 1.0/ 13 Dec 2012/AM D 11medication again (respective patients must be withdrawn from the trial). In 
case of shorter interruptions, it is at the discretion of the investigator if the 
study  medication can be restarted.
In case of pregnancy  or breast feeding .
Participation in another clinical trial
In case that the patient fulfills one of the stopping criteria specified in 
Section 4.5.7 “Prior and Concomitant Therap y”.
In case no further dose reduction is possible and patient does not tolerate the 
lowest possible BAY 63-2521 dose (0.5.mg tid) .
Patients who withdraw should take part at the Termination Visit and the Safety 
Follow Up Visit (refer to Section 4.6.3 ).Moreover, it is the investigator’s 
responsibility , in case of permanent discontinuation of the study  medication, to 
decide together with the patie nt about the initiation of an alternative treatment.
4.4 Premature Termination of Study/Closure of Centre
The sponsor has the right to close this study , and the investigator/sponsor has the 
right to close a centre , at any time, although this should occur only after 
consultation between involved parties. The EC/IRB must be informed. 
Reasons to close the study prematurel y ma y be for example:
If patients can be transferred to another clinical study  or treatment program 
with BAY 63-2521 that ensures that patients who benefit can be treated with 
the compound until the drug receives official approval and will be 
commerciall y available.
The occurrence of a new relevant safet y related finding that has a negative 
impact on Risk -Benefit Ratio of the compound.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 16of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Should the study /centre be closed prematurely , all study  materials (except 
documentation that has to remain stored at site) must be returned to the sponsor. 
The investigator will retain all other documents until notification given by the 
sponsor for destruction.
4.5 Treatments
4.5.1 Treatments to be administered
Test-Drug: BAY 63-2521
Dosage: 1.0-2.5mg(Individual Dose Titration)a
Route of administration: oral
Time and frequency  of administration: tidb
aIn case of side effects ( egsymptom atic hypotension) doses of 0.5 m gtid are allow ed
bThe respective single daily doses should be taken 6 -8 hours apart.
(For the individual dose titration refer to Section 4.1.)
4.5.2 Identity of Investigational Product(s)
Study  medicat ion will be labeled according to the requirements of local law and 
legislation. Label text will be approved according to agreed Bay er procedures, and a 
copy  of the labels will be made available to the study  site upon request.
BAY 63-2521 will be provided by BAYER Clinical Drug Supplies as tablets at a 
dose of 0.5mg ,1mg, 1.5 mg, 2mg and 2.5mg . The 5 tablets strengths are identical in 
appearance.
BAY 63-2521 tablets will be packed in HDPE bottles.
Storage requirements
All investigational drugs used during the trial will be stored at the investigational 
sites in a place inaccessible to unauthorized personnel, ie a locked cabinet.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 17of 75
Final Version 1.0/ 13 Dec 2012/AM D 114.5.3 Method of Assigning Patient s to Treatment Groups
Not applicable
4.5.4 Selection of Doses in the Study
The dose selection for this study  was based on the following rationale:
The dose range of 1.0 -2.5 mg tid was tested in healthy  volunteers in a multiple -
dose study  (# 11260). The highest dose of 2.5 mg tid showed a clear increase in 
adverse events and further escalation was stopped. A dose of 0.5 mg was identified 
in healthy  volunteers (study  11258) as the no-effect dose while 1.0 mg alread y 
showed clinicall y relevant hemody namic effects in some patients in the proof of 
concept study  11874. In the same study  a strong lowering of systemic blood 
pressure was observed in one patient at the highest dose level (5 mg). Therefore 1.0 
mg tid was selected as the minimal dose and 2.5 mg tid as the maximum dose for 
further studies in patients (for further details refer to the Investigator Brochure). In
an ongoing Phase II trial (12166) in patients with PAH and CTEPH the respective 
dose range is tested in combination with an individual dose titration scheme. Based 
on interim analy ses dose between 1.0 mg tid and 2.5 mg tid are effective and safe.
4.5.5 Selectio n and Timing of Dose for Each Patient
BAY 63-2521 willbe administered tid as I R tablets with or without food.
During the eight week slasting Titration Phase , patients from the Placebo Arm and 
from the BAY 63-2521 1.5 mg Dose Arm (applies only to patients who reached the 
1.5 mg tid level )of PATENT -1 trial will be up-titrated, if tolerated, up to 2.5 mg 
BAY 63-2521 tid according to theindividual dose titration scheme. In contrast to 
that, patients from the PATENT -1 Individual Dose Titration Arm will remain on 
their “optimal dose” from PATENT -1 (for further details refer to Section 4.1).
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 18of 75
Final Version 1.0/ 13 Dec 2012/AM D 11After anindividual BAY 63-2521 dose has been determined   all patients will enter
the Main -Study  Phase (Visit 5). During the Main -Study  Phase investigators are 
allowed to modify  the BAY 63-2521 dose according to the patients need. In contrast 
to the Titration Phase, patients may be up-titrated between regular schedule dvisits.
The maximum allowed BAY 63-2521 dose is 2.5 mg tid, the minimum 0.5 mg tid
(for further details refer to Section 4.1).
4.5.6 Blinding
Titration P hase:
To ensure the blind ingof the treatment regimen of PATENT -1 study , the dosing of 
BAY 63-2521 will be kept blinded during the Titration Phase of PATENT -2.
Main Study Phase:
During the Main-Study Phase the blinding of dosing will be removed and patien ts 
will be treated with “open label ” medication .
4.5.7 Concomitant Therapy
The intake of the following concomitant medications is not allowed during the 
Titration Phase and the Main -Study  Phase of the trial:
Specific (egSildenafil or Tadalafil) or unspecific Phosphodiesterase
Inhibitors ( egDipy ridamole, Theophy lline)
NO donors ( egNitrates)
Patients, who require respective medica tions, need to be withdrawn from the study 
(refer to Section 4.3“Removal of Patients from Study ”).
Treatment na ive patients from PATENT -1
It is not allowed to start a concomitant Endothelin Receptor Antagonists -/ 
Prostacy clineAnalogues therap y during the Titration Phase of the trial (after Visit 5 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 19of 75
Final Version 1.0/ 13 Dec 2012/AM D 11concomitant treatment is allowed) . Patients, who require a concomitant Endothelin 
Receptor Antagonists -/ Prostacy clineAnalogues therap yduring the Titration Phase
need be withdraw n from the study  medication (refer to Section 4.3“Removal of 
Patients from Study ”).
Patients pre-treated with an Endothelin Receptor Antagonist or a 
Prostacyclin eAnalogue from PATENT -1
It is not allowed to modify  the concomit ant Endothelin Receptor Antagonists -/ 
Prostacy clineAnalogues therap y (egdosage, type of medication) during the 
Titration Phase of the trial (After Visit 5 therapy  modifications are allowed) . 
Patients who require a modification of their Endothelin Recept or Antagonists -/ 
Prostacy clineAnalogues therap yduring the Titration Phase need to be withdrawn 
from the study  medication (refer to Section 4.3“Removal of Patients from Study ”).
Other concomitant therapy
Due to possible pharm acokinetic interactions between BAY 63-2521 and 
strong CYP3A4 inhibitors (eg Ketoconazol) concomitant treatment should 
be applied with caution (eg additional blood pressure monitoring). Such 
drugs may significantl y increase BAY 63-2521 plasma concentration s. In 
this context, dose reduction of BAY 63-2521 should be considered (eg –0.5 
mg tid), in particular if the patient suffers a clinical relevant decrease in 
blood pressure (eg systolic blood pressure <90 mmHg with clinical 
symptoms). For further informat ion refer to the Investigator Brochure.
Antacids like aluminum hydroxide/magnesium hydroxide (eg Maaloxan ®) 
should not be taken simultaneously  with BAY 63-2521, because a negative 
impact on the bioavailability  of the study  drug has been observed (please 
refer to the Investigator Brochure). To avoid such kind of interaction, 
antacids should be taken 1 hour after intake of BAY 63-2521 at the earliest.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 20of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Pre-and co-treatment with Omeprazole led to a  decrease in BAY 63-2521 
bioavailability , indicating a lower bioavailability  of BAY 63-2521 in neutral 
versus acidic milieu (for further information refer to the Investigator 
Brochure).
Preliminary  inspection of trough and peak plasma concentrations of 
BAY 63-2521 and BAY 60-4552 (Main BAY 63-2521 metabolite) in a 
cohort of patient s treated with bosentan (n=6) compared to the patient s not 
treated with bosentan (n=66) clearl y indicate a decrease in 
BAY 63-2521/BAY 60-4552 plasma exposure, most probably  due to the 
known CYP3A4 enzyme-inducing effects of concomitant bosentan. 
However, patient s treated with bosentan profited in about the same 
magnitude in the 6 minute walk test as patient s in the therapy  naïve cohort 
did (for further information refer to the Investigator Brochure, trial 12166).
Participation at a supporti ve physical training program , defined as a 
structured exercise and rehabilitation program supervised by a physician 
and/or a physiotherapist is not allowed during the Titration Phase of the 
study . However, later on during the Main Study  Phase participation at 
respective training program is allowed, but need to be documented in the 
electronic CRF.
Concomitant treatment in case of clinical deterioration
In case of a clinical lyrelevant deterioration of the patient’s signs or s ymptoms of 
pulmonary  hypertension the investigator may  consider startingan alternative 
treatment with Endothelin Receptor Antagonists, and/or Prostacy clineAnalogues, 
and/or Phosphodiesterase Type-5 Inhibitors or to modify  a preexisting Prostacy cline
Analogues treatment ( ieincrease of n umber of daily  Iloprost inhalations from 6 to 9, 
or increase of Iloprost dosage from 2.5 to 5.0 microgram per inhalation, or start of an 
iv Prostacy clineAnalogue) at an y point in time.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 21of 75
Final Version 1.0/ 13 Dec 2012/AM D 11In case that the administration of the treatment is in conflict with t he limitations 
mentioned above, the treatment with the study  drug needs to be terminated (refer to 
Section 4.3“Removal of Patients from Study ”).
Due to possible sy nergist iceffects on blood pressure Phosphodiesterase Type -5 
Inhibitors should only  be administered after an appropriate wash out time of 24 
hours after last intake of BAY 63-2521 .
4.5.8 Treatment Compliance
The packages of the investigational drug have to be brought back to the 
investigational site, and tablets will be counted for a compliance check. The 
respective compliance should be between 80% and 120% of calculated dose. 
Moreover, plasma concentrations will give additional information about patients' 
compliance.
4.6 Study Variables
The objective of the tr ial is to assess safet y and tolerability of long -term treatment 
of BAY 63-2521 in patients with symptomatic PAH .In addition, efficacy 
assessments are included to provide an indication of maintenance of efficacy  with 
long term treatment.
4.6.1 Safety Variable s
Treatment emergent adverse events
Treatment emergent serious adverse events
Laboratory  parameters
Blood pressure
Heart rate
ECG
Blood gas parameter
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 22of 75
Final Version 1.0/ 13 Dec 2012/AM D 114.6.2 Other Variables
Change from baseline in 6 Minute Walking Distance
Change from baseli ne in NT -pro BNP
Change from baseline in WHO functional class
Time To Clinical Worsening
Change from baseline in Borg CR 10 Scale or Modified Borg Dy spnoea 
Scale (if patient swere enrolled intrial 12934 before a mend ment 4 approval 
in their countries )(mea sured at the end of the 6MWD Test)
Change from baseline in EQ -5D questionnaire
Change from baseline in L PHquestionnaire
Change in use of healthcare resources
4.6.3 Assessment Periods
Visit 1 at Day 0
Patients who finalized at Visit 6 the PATENT -1 trial and unde rwent invasive 
hemody namic measurements may remain in the clinic until the next day (optional 
hospital stay ).
At the day after finalization of PATENT -1 trial (= Visit 1 of PATENT -2), patients 
who fulfill the in/exclusion criteria and signed the informed consent form will be 
included into PATENT -2.
Please Note: it is not permitted to include a patient into the extension study on the 
same day of V6of PATENT -1 (applies even if Visit 6investigations were 
performed at two consecutive day s).
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 23of 75
Final Version 1.0/ 13 Dec 2012/AM D 11On Visit 1 prior to first administration of PATENT -2 study  medication, blood 
pressure and heart rate will be measured.
Subsequently , the patients will be allocated via the IVR-System to their individual 
BAY 63-2521 starting dose. In this context, the IVR-System will consi der the 
patient’s treatment arm allocation from the PATENT -1 trial (for further details refer 
to Section 4.1).
Two to three hours after the first intake of study medication, blood pressure and 
heart rate measurement will be repeated (for further details about the order of the 
procedures and the temporal relationship refer to Section 10.1).
Between six to eight hours after first study  medication intake, the patients should
take the second dose of study medication (second measurement cycle). One to zero 
hours before intake of second dose of study  medication, blood pressure and heart 
rate will be measured , pharmacokinetic blood samples will be collected and a 12-
lead electrocardiogram will be recorded . 2-3 hours after intake of second dose of 
study  medication the blood pressure and heart rate should be measured (for further 
details about the order of the procedures and the temporal relationship refer to 
Section 10.1).
In addition to the measurements related to themeasurement cycles, Adverse Events 
will be questioned and documented. Adverse events that occur before intake of first 
dose of PATENT -2 medication will be allocated to PATENT -1.
The study  medication should be taken sixto eight hours apart. If during the profile 
visit the systolic blood pressure falls below 90mmHg with clinical symptoms of 
hypotension such as dizziness or presy ncope, the study  medication should be 
reduced b y 0.5 mg tid or if deemed necessary  interrup ted (see section 4.1).
If there are no medical objections, the patients will be discharged, after the second 
measurement cycle(blood pressure and heart rate are the main hemody namic safety 
parameters that need to be considered ).In this context, study  medication for the 
next two weeks will be dispensed.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 24of 75
Final Version 1.0/ 13 Dec 2012/AM D 11In case of medical objections (e.g. low blood pressure) patients should be 
hospitalized until a stable status is achieved (optional hospital stay ).
During out-patient treatment until Visit 5, the patients will document the intake of 
the study  medication on a patient diary which they will receive at Visit 1. The 
patients will return the patient diary to the investigator at each study  visit until Visit 
5. The exact time points of the last 3preceding doses before the ambulatory  visit 
will be documented in the CRF.
Note: All blood pressure , heart rate measurements and ECGs should be performed 
in supine position at rest (for more details refer to Section 4.6.4 ).
Visit 2 at Day 14 / Visit 3 at Day 28 / Visit 4 at Day 42a
adeviations from  the scheduled visits of ±2 days are permissible
Patients will return to hospital for an ambulatory  assessment every  2weeks without 
taking their morning dose of study  medica tion. Before the dose of the study 
medication will be adjusted according to the titration scheme (refer to Section 4.1), 
blood pressure and heart rate will be measured, blood samples for clinical 
chemistry , hematology , coagulat ion parameters, NT-pro BNP will be collected, and 
a 12-lead electrocardiogram will be recorded.
Subsequently , based on the patient’s SBP at trough, an individual decision with 
respect to a dose modification will be made (for further details refer to Sectio n4.1). 
The respective decision will be entered into the IVR-System. Afterwards, under 
consideration of the IVR-System’s reply, the study  medication for the next 2 weeks 
will be dispensed to the patients.
Two to three hours after intake of the morning dose of study  medication, blood 
pressure and heart rate measurement will be repeated (for further details about the 
order of the procedures and the temporal relationship refer to Section 10.1).
Four to fivehours after the intake of the morning dose of study  medication 6MWD 
Test and an evaluation of Borg CR 10 Scale or Modified Borg Dyspnoea Scale (if 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 25of 75
Final Version 1.0/ 13 Dec 2012/AM D 11applicable ) will be performed (for further details about the order of the procedures 
and the temporal r elationship refer to Section 10.1).
.
In case that the SBP drops after intake of the morning dose below 90 mmHg with 
clinical symptoms of hypotension such as dizziness or presy ncope, the study  
medication should be reduced by 0.5mg tid or if deemed necessary  interrupted for 
safet y reasons (see section 4.1).
In addition to the measurements related to the cycle of measurements, the patient’s 
concomitant medication will be updated , healthcare resource information will be 
collected , WHO functional class will be assessed ,  smoking status and Events of 
Special Interest as well as Adverse Events will be questioned and documented in the 
CRF.
The patients will be asked to return all unused study  medication andthe patient 
diary from the former visit for a compliance check. 
Note: All blood pressure , heart rate measurements and ECGs should be performed 
in supine position at rest (for more details refer to Section 4.6.4 ).
Visit 5 at Day 56a
adeviations from  the scheduled visit of ± 2 days are permissible
Patients will return to hospital for an ambulatory  assessment without taking their 
morning dose of study  medication. Before the dose of the study  medication will be 
adjusted according to the titration scheme (refer to Section 4.1), blood pressure and 
heart rate will be measured, blood samples for clinical chemistry , hematology , 
coagulation parameters, NT-pro BNP, and pharmacokinetics will be collected, and a 
12-lead electrocardiogram will be recorded. In addition, the patients will be asked to 
complete the EQ-5Dand the L PH questionnaires.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 26of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Subsequently , based on the patient’s SBP at trough, an individual decision with 
respect todose modifications will be made (for further details refer to Section 4.1). 
The respective decision will be entered into the IVR-System. Afterwards, under 
consideration of the IVR-System’s reply, the study  medication for the next 4 weeks 
will be dispensed to the patients (Note: from that point in time on, the dose of the 
study  medication will be unblinded).
Two to three hours after intake of the morning dose of study  medication, blood 
pressure and heart rate measurement will be repeated (for further details about the 
order of the procedures and the temporal relationship refer to Section 10.1).
Four to five hours after the intake of the morning dose of study  medication 6MWD 
Test and an evaluation of Borg CR 10 Scale or Modified Borg Dyspnoea Scale (if 
applicable ) will be performed (for further details about the order of the procedures 
and the temporal relationship refer to Section 10.1).
.
In case that the SBP drops after intake of the morning dose below 90 mmHg with 
clinical symptoms of hypotension such as dizziness or presy ncope, the study  
medication should be reduced by 0.5mg tid or if deemed necessary  interrupted for 
safet y reasons (see section 4.1).
In addition to the measurements related to the cycle of measurements, the patient’s 
concomitant medication will be updated , healthcare resource information will be 
collected , WHO functional class will be assessed, smoking status and Events of 
Special Interest as well as Adver se Events will be questioned and documented in the 
CRF.
The patients will beasked to return all unused study  medication and the patient 
diary from the former visit for a compliance check. The exact time points of the last 
3preceding doses before the ambu latory  visit will be documented in the CRF.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 27of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Note: All blood pressur e, heart rate measurements and ECGs should be performed 
in supine position at rest (for more details refer to Section 4.6.4 ).
Visit 6 a(changed with amendment 11)
adeviations from  the scheduled visit of ± 2 days are permissible 
Patients will return to hospital for an ambulatory  assessment at Visit 6 without 
taking their morning dose of study  medication.
Before the patients take the morning dose of the study  medication, a physical 
examination will be done and the patient’s weight recorded, blood pressure and 
heart rate will be measured, blood samples for clinical chemistry , hematology , 
coagulation parameters, blood gas analysis, NT-pro BNP will be collected, and a 
12-lead electrocardiogram will be recorded. In addition, the patients will be asked to 
complete the EQ-5Dquestionnaire.
Subsequently , the investigator will make a decision (needs to be entered into the 
IVR-System) with respect to the patient’s BAY 63-2521 dose for the next treatment 
period. In this context, the investigator will consider the patient’s blood pressure 
(refer to the individual dose titration scheme Section 4.1), potential BAY 63-2521 
side effects and the progre ssion of the underl ying Pulmonary  Hypertension.
Two to three hours after intake of the morning dose of study  medication , blood 
pressure and heart rate measurement will be repeated (for further details about the 
order of the procedures and the temporal rela tionship refer to Section 10.1).
Four to five hours after the intake of the morning dose of study  medication 6MWD 
Test and an evaluation of Borg CR 10 Scale or Modified Borg Dyspnoea Scale (if 
applicable ) will be performed (for further details about the order of the procedures 
and the temporal relationship refer to Section 10.1).
In case that the SBP drops after intake of the morning dose below 90 mmHg with 
clinical symptoms of hypotension such as dizziness or presy ncope, the study  
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 28of 75
Final Version 1.0/ 13 Dec 2012/AM D 11medication should be reduced by 0.5mg tidor if deemed necessary  interrupted for 
safet y reasons (see section 4.1).
In addition to the measurements related to the cycle of measurements, the patient’s 
concomitant medication will be updated , healthcare resource information will be 
collected , WHO functional class will be assessed, smoking status and Events of 
Special Interest as well as Adverse Events will be questioned and documented in the 
CRF.
The patients will be asked to return all unused study  medication .
For female patients with child bearing potential a pregnancy  test will be performed.
Unblinded study  medication will be dispensed for the next 90 day s.
Note: All blood pressure , heart rate measurements and ECGs should be performed 
in supine position at rest (for more details refer to Section 4.6.4 ).
Visit 7 –Vn (every 90 days)a* (added with amendment 11)
adeviations from  the scheduled visit of ± 14 days are perm issible 
Patients will return to hospital for an ambulatory  assessment without taking their 
morning dose of study  medication.
Before the patients take the morning dose of the study  medication, a physical 
examination will be done and the patient’s weight recorded, blood pressure and 
heart rate will be measured .
Subsequently , the investigator will make a decision (needs to be entered into the 
IVR-System) with respect to the patient’s BAY 63-2521 dose for the next treatment 
period. In this context, the investi gator will consider the patient’s blood pressure 
(refer to the individual dose titration scheme Section 4.1), potential BAY 63-2521 
side effects and the progression of the underl ying Pulmonary  Hypertension.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 29of 75
Final Version 1.0/ 13 Dec 2012/AM D 11One hour after the intake of the morning dose of study  medication 6MWD Test will 
be performed . 
In case that the SBP drops below 90 mmHg with clinical symptoms of hypotension 
such as dizziness or presyncope, the study  medication should be reduced by 0.5mg 
tid or if deemed ne cessary  interrupted for safet y reasons (see section 4.1).
In addition to the measurements related to the cycle of measurements, the patient’s 
concomitant medication will be updated , WHO functional class will be assessed and 
Events of Special Interest as well as Adverse Events will be questioned and 
documented in the CRF.
The patients will be asked to return all unused study  medication.
For female patients with child bearing potential a pregnancy  test  must be performed 
locally .
Unblinded study  medication will be dispensed for the next 90 day s.
Note: All blood pressure, heart rate measurements should be performed in supine 
position at rest (for more details refer to Section 4.6.4 ).
Term ination Visit
In case the decision has been made to stop the study medication prematurely or if 
the sponsor announces the official end of the study , a Termination Visit should be 
performed at the respective point in time or as soon as possible after stop of 
medication. In general, at the Termination Visit the same efficacy  and safety  
relevant measurements should be performed as at Visit n (Exception: no pregnancy 
test needs to be performed). In particular, every  effort should be made to perform 
the 6MWD Tes t.Deviations need to be documented in the electronic CRF.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 30of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Safety Follow Up Visit 30 days after stop of study medicationa
adeviations from  the scheduled visit of +5days are perm issible
For all patients who stopped the study  medication either at the official end of the 
trial or prematurely , a Safet y Follow -Up Visit 30 days after last study  medication 
intake has to be performed.
At the Safet y Follow Up Visit the following assessments should be performed: 
physical examination including determination of patient’s weight , blood pressure 
and heart rate measurement (changed with amendment 11) .
For female patients with child bearing potential a pregnancy  test must be performed
locally . Moreover, adverse events will be questioned and the concomitant 
medication pag es in the electronic CRF will be updated.
Note: All blood pressure and heart rate measurements should be performed in 
supine position at rest (for more details refer to Section 4.6.4 ).
4.6.4 Observations and Measurements
(Visits and numbering updated with amendment 11)
Laboratory Parameters
All blood samples will be anal yzed in a central laboratory until V6 .
Laboratory  procedures will be described in a separate laboratory  manual .
At the latest at the end of the study  when all planned analyses are completed, all 
blood sample swill be destroy ed.
Hematology, clinical chemistry, coagulation test
Hematology  (white blood cell differential count, erythrocy tes, hemoglobin, 
hematocrit, platelets)
Coagulation tests (PTT, INR)
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 31of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Clinical chemistry (AST, ALT, ALP, GGT, GLDH ,CK, lipase, CHE, creatinine, 
urea, uric acid, total bilirubin, total protein, serum albumin, sodium, potassium , 
calcium, phosphate)
Note: Calcium and phosphate will only be analyzed for patients who were included 
under amendment 8 of study 12934 .
Frequency : At every  visit until V6(except Visit 1 )
NT-proBNP
Frequency : At every  visit until V6with the exception of Visit 1 and Safety Follow 
Up Visit
Changes from baseline NT-proBNP will be considered as a secondary efficacy 
endpoi nt in PATENT -1. To ensure the blinding of the treatment regime of 
PATENT -1, the results of the NT -pro BNP determinations at PATENT -2 Visits 2 -5 
will not be forwarded to the investigators before lock of the PATENT -1 database. In 
contrast to that the resul tsof the NT-pro BNP determination at PATENT -2,Visit 6 
will be forwarded to the investigators.
Pregnancy testing
Methodology : Determination of ß -human chorionic gonadotropin in blood serum or 
urine
Frequency : Will be performed centrall y at Visit 6 and locallyat least at every  Main -
Study  Phase Visit (V7-Vn) and at Safety  Follow Up Visit. Based on country  
specific regulations further measurements might be performed.
In addition to the above mentioned serum ß-human chorionic gonadotropin tests, a 
urine test will be performed at Visit 6 of PATENT -1 study if the patient will 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 32of 75
Final Version 1.0/ 13 Dec 2012/AM D 11participate in the extension study . Female patients with childbearing potential can 
be enrolled into the extension study  based on the result of this test.
Blood gas analysis
SaO2(%)
PaO2(mmHg
PaCO 2(mmHg)
Supplemental oxygen   “yes” or “no” (If the patient receives supplemental oxygen 
the amount will be recorded in the electronic CRF in liter per minute)
Methodology : Capillary  or arterial blood gas analy sis
Frequency : At V6 
Blood pressure a nd heart rate measurement
Blood pressure and heart rate will be measured after the patient has been at rest for 
10 minutes in a supine position. The same arm is alway s used for these 
measurements.
Methodology : Non invasive measurement preferabl y with a mercury 
sphygmomanometer or a validated electronic device in accordance with published 
guidelines (egAmerican Heart Association. Recommendations for Blood Pressure 
Measurement in Humans and Experimental Animals. Hypertension 2005;45;142 -
161)
Frequency : At every  visit
Point in time: For details refer to appendix 10.1
Electrocardiography
For deriving the ECGs the patient should alway s be in supine position. The ECGs 
should be derived after a resting period of 15min. The ECGs for the study  will be 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 33of 75
Final Version 1.0/ 13 Dec 2012/AM D 11transferred electronically and assessed centrall y. In addition, the investigator will 
print -out the ECGs locally and review the ECGs for potential AEs.
ECG procedures will be described in a separate manual.
Methodo logy: 12 lead ECG
Frequency : Every  visit until V6
Point in time: For details refer to appendix 10.1
Exercise Testing / 6 Min Walking Distance (6MWD) Test
The 6 Min Walking Distance Test will be performed in accordance with the
American Thoracic Society  Guideline. 
Methodology : During the Titration Phase the test has to be performed by a second 
person who is not involved in the process of study  drug titration and is unaware of 
the immediate reaction of the patient’s blood pressu re and heart rate after dosing. 
This person will enter the t est results on a separate work sheet and a different person
(could be the same person as involved in titration) will enter them into the electronic 
CRF.
Frequency : At every  visit with the exceptio nof Visit 1 and Safety  Follow -Up Visit
Point in time: For details refer to section 4.6.3 and appendix 10.1For further details 
refer to Section 10.4.
Borg CR 10 Scale®orModified Borg Dyspnoea Scale 
The Borg CR 10 Scale or Modified Borg Dyspnoea Scale (if patient was enrolled 
before 12934 Amendment 4 approval in their country )will be measured together 
with 6MWD Test. 
Methodology : The test will be explained to the patie nts before starting the 6MWD 
test. The patients will be asked to rank their exertion at the end of the 6MWD test.
During the Titration Phase the test has to be performed by a person who is not 
involved in the process of study  drug titration and is unaware of the immediate 
reaction of the patient’s blood pressure and heart rate after dosing. This person will 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 34of 75
Final Version 1.0/ 13 Dec 2012/AM D 11enter the testresults on a separate work sheet and a different person (could be the 
same person as involved in titration) will enter them into the elect ronic CRF.
In context with 12934 protocol amendment 4 the “Modified Borg Dyspnoea Scale” 
was replaced by the Borg CR 10 Scale®. For consistency  reason, patients who were 
enrolled before approval of 12934 protocol amendment 4 in their country  must use 
the “ Modified Borg Dy spnoea Scale” throughout the main and the extension study .
Frequency : At every  visit until V6with the exception of Visit 1 and Safet y Follow
Up Visit
Point in time: I mmediately  after the 6MWD Test
For further details refer to section 4.6.3 and Section 10.5.
Determination of WHO Functional Class
The patient’s functional class will be determined according to the WHO 
classification.
Methodology : During the Titration Phase the evaluation has to be performed by a 
second physician who is not involved in the process of study  drug titration and is 
unaware of the immediate reaction of the patient’s blood pressure and heart rate 
after dosing. This phy sician will enter the test results on a separ ate work sheet and a 
different person (could be the same person as involved in titration) will enter them 
into the electronic CRF.
Frequency : At every  visit with the exception of Visit 1 and Safety  Follow -Up Visit
For further details refer to Section 10.6.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 35of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Events of Special Interest
Time To Clinical Worsening
The first occurrence of the following events of special interest need to be 
documented in the electronic CRF and will be considered for the calculation of the 
combined endpo int “Time To Clinical Worsening”:
Death (all -cause mortality )
Heart/lung transplantation
Atrial septostomy  (AS)
Hospitalization due to persistent worsening of Pulmonary  Hypertensiona,b
Start of new PH specific treatment (Endothelin Receptor Antagonists, 
Prostacy clineAnalogues, Phosphodiesterase Type-5 Inhibitors) or 
modification of a preexisting Prostacy clineAnalogues treatment (ie increase of 
number of daily Iloprost inhalations from 6 to 9, or increase of Iloprost dosage 
from 2.5 to 5.0 microgram per inhalation, or start of an iv Prostacy cline
Analogue) due to worsening Pulmonary  Hypertension.
Persistent decrease of more than 15 % from baseline or more than 30% 
compared to the last study  related measurement in 6MWD due to worsening 
pulmonary  hypertensionb.
The persistence of the decrease has to be confirmed by a second measurement 
performed after 14 day s. In case that the period between first occurrence of the 
event and the Termination Visit is less than 14 days, the decrease needs to be 
confirmed at the Termination Visit.
Persistent worsening of functional class due to deterioration of Pulmonary  
Hypertensionb:
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 36of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Patients who deteriorate from class II or III to class IV: The persistence of 
worsening has to be confirmed by a second measurement performed after 14 
days. In case that the period between first occurrence of the event and the 
Termination Visit is less than 14 days, the decrease needs to be confirmed at 
the Termination Visit.
Other Events of Special Interest
The first occurrence of the following even t of special interest needs to be 
documented in the electronic CRF, but will not be considered for the calculation of 
the combined end point “Time To Clinical Worsening”:
Initiation of a supplemental long-term oxygen therapy  (=oxygen application 
for more than 30 days at a stretch ) or persistent modification of a pre-existing 
supplemental long term oxy gen therap y (ie need for a persistent increase of the 
amount of delivered oxygen for more than 30 days) due to worsening 
pulmonary  hypertension.b
aTransient deteriorations of clinical status requiring hospitalization, treatable by eg short time 
application of iv diuretics, positive inotropic agents or non -invasive ventilation and allowing patients 
discharge within 48 hours are not considered as persistent with respect to the event of special interest 
definition.
bIn case of clinical deterioration the investigator has to assess carefully if the deterioration of the 
patient’s condition (eg worsening functional class) is related to the underlying pulmonar y 
hyperten sion or can be explained by an alternative cause (eg transient infection, musculoskeletal 
disease, surgical or medical intervention other than PH related, exacerbation of a concomitant lung 
disease, lacking compliance of medication intake). Only persistent clinical deteriorations caused by 
the underlying pulmonary hypertension will be considered as events of special interest.
Frequency : At every  visit with the exception of Visit 1 and Safety  Follow -Up Visit 
the investigator must check if an event of special interest has occurred in the period 
between start and termination of the study  drug treatment. With respect to each 
subcategory  (eg “hospitalization due to persistent worsening of pulmonary  
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 37of 75
Final Version 1.0/ 13 Dec 2012/AM D 11hypertension”) it is only  necessary  to document the first occurre nce of such an event 
in the electronic CRF.
HEOR measurement s
EQ-5D, LPH
EQ-5Dand LPHare health questionnaire sthat evaluate the patient’s health status 
and quality  of life.
Methodology : Questionnaires need to be self -completed by  the patients
EQ-5D Frequency :V5and V6 only
LPHFrequency : Visit 5only.
For further details refer to Section 10.7and Section 10.8.
Use of healthcare resources
For health economic calculations (see section 4.6.2 ) investigators need to collect 
information about the use of healthcare resources. This includes information about:
Visits at healthcare professionals (eg t ype of healthcare professional visited)
Hospitalizations and rehabilitation proc edures (eg start and stop date of 
hospitalization)
Diagnostic and therapeutic procedures (eg ty pe of diagnostic procedure)
Frequency : From Visit 2until Visit 6investigators need to collect on a nongoing 
basis information about health care resources that the patient uses since intake of the 
first dose of PATENT -2 study  medication. The respective information will be 
recorded in the electronic CRF.
4.6.5 Drug Concentration Measurements
For investigation of drug exposure and potential relationships to drug effects,
plasma concentrations of BAY 63-2521 (and its main metabolite BAY 60-4552 ) 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 38of 75
Final Version 1.0/ 13 Dec 2012/AM D 11will be determined at the times given in the Trial Flow Chart (see Section 10.1) and 
in the Appendix 10.2using a sparse sa mpling approach in all participating patients .
Frequency : Visit 1 and Visit 5
BAY 63-2521 and metabolite M -1 (BAY 60-4552 ) concentrations in plasma will be 
measured by a validated HPLC-MS/MS method. Quality  control (QC) and 
calibration samples will be anal yzed concurrently with study  samples. The results of 
QC samples will be reported together with concentrations in unknown samples in 
the MRR of this study .Drug concentrations are calculated from the 
chromatographic raw data in accordance with current Bayerguidelines (see Section 
9). The data are evaluated using CCW software in its most recentl y released 
version.
4.7 Data Quality
Monitoring and auditing procedures defined/agreed by  the sponsor will be followed, 
in order to comply  with GCP guidelines. Each centre will be visited at regular 
intervals by a monitor to ensure compliance with the study  protocol, GCP and legal 
aspects. This will include on-site checking of the case report forms (CRF) for 
completeness and clarity, cross -checking with source documents, and clarification 
of administrative matters .
4.8 Documentation
An electronic data capture system will be used in this study  (e-CRF). All entries 
made in the e-CRF must be verifiable against source documents.  The source data 
param eter to be verified and the identification of the source document must be 
documented. The study  file and all source data should be retained until notification 
given b y the sponsor for destruction .
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 39of 75
Final Version 1.0/ 13 Dec 2012/AM D 115.ETHICAL  AND LEGAL  ASPECTS
5.1 Ethics Committee (EC) or Institu tional Review Board (IRB)
Documented approval from appropriate Ethics Committee(s)/I RBs will be obtained 
for all participating cente rs/countries prior to study  start, according to GCP, local 
laws, regulations and organizations. When necessary , an extension , amendment or 
renewal of the Ethics Committee approval must be obtained and also forwarded to 
the sponsor. The Ethics Committees must supply  to the sponsor, upon request, a list 
of the Ethics Committee members involved in the vote and a statement to confi rm 
that the Ethics Committee is organized and operates according to GCP and 
applicable laws and regulations.
5.2 Ethical Conduct of the Study
The procedures set out in this protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the sponsor and investigator 
abide by Good Clinical Practice Guidelines and under the guiding principles 
detailed in the Declaration of Helsinki. The study  will also be carried out in keeping 
with applicable local law(s) and regulat ion(s). This may include an inspection by 
the sponsor representatives and/or Regulatory  Authority  representatives at any time.  
The investigator must agree to the inspection of study -related records by the 
Regulatory  Authority /sponsor representatives, and must allow direct access to 
source documents to the Regulatory  Authority /sponsor representatives. 
Modifications to the study  protocol will not be implemented by  either the sponsor or 
the investigator without agreement by both parties. However, the investi gator may 
implement a deviation form, or a change of, the protocol to eliminate an immediate 
hazard(s) to the trial patient s without prior EC/IRB/Sponsor approval/favorable 
opinion. As soon as possible, the implemented deviation or change, the reasons for 
it and if appropriate the proposed protocol amendment should be submitted to the 
EC/IRB/Sponsor. Any deviations from the protocol must be fully explained and 
documented b y the investigator.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 40of 75
Final Version 1.0/ 13 Dec 2012/AM D 115.3 Regulatory Authority Approvals/Authorizations
Regulatory  Authorit y approvals/authorizations/ notifications, where required, must 
be in place and fully  documented prior to study  start.
5.4 Patient Information and Consent
A core Information and Informed Consent Form will be provided. Prior to the 
beginning of the study , the investigator must have the ECs/IRB written 
approval/favorable opinion of the written Informed Consent Form and any other 
written information to be provided to patient s. The written approval of the EC/IRB 
together with the approved Patient Information/Infor med Consent Forms must be 
filed in the study  files.
Written informed consent must be obtained before any study  specific procedure 
takes place. Participation in the study  and date of informed consent given by the 
patient should be documented appropriatel y in the patient ’s files.
5.5 Insurance
All patient s participating in the study  will have insurance coverage by the sponsor, 
which is in line with applicable laws and/or regulations.
5.6 Confidentiality
All records identify ing the patient will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly  
available. 
Patient names will not be supplied to the sponsor. Only  the patient number will be 
recorded in the case report form, and if the patient name appea rs on any other 
document (eg, pathologist report), it must be obliterated before a copy  of the 
document is supplied to the sponsor.  Study findings stored on a computer will be 
stored in accordance with local data protection laws.  The patient s will be informed 
in writing that representatives of the sponsor, EC/I RB, or Regulatory  Authorities 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 41of 75
Final Version 1.0/ 13 Dec 2012/AM D 11may inspect their medical records to verify  the information collected, and that all 
personal information made available for inspection will be handled in strictest 
confidence and in accordance with local data protection laws.
If the results of the study  are published, the patient ’s identit y will remain 
confidential. 
The investigator will maintain a list to enable patient s’ records to be identified.
6.STATISTICAL  METHODS AND DETERMINA TION OF  SAMPLE 
SIZE
6.1 Statistical and Analytical Plans
The aim of this long-term extension study  is primarily the assessment ofsafety  and 
tolerability , so no single primary  variable has been identified. Patient numbers will 
be determined by those completing the PATENT -1 study  and willing to enter the 
PATENT -2 study . As the extension is of an open label design with no comparator 
group , all statistical analy ses will be descriptive. The summary  tables will be 
presented for the overall group of patients, and also split by previous treatment 
group sin PATENT -1. Baseline will be week 0 in PATENT -1(changed with 
amendment 11) . 
Statistical analysis of safety variables
For the analysis of safet y, all patient s entering PATENT -2 and receiving 
BAY 63-2521 will be included. For treatment -emergent adverse events, ECG and 
laboratory  test abnormalities, frequency  counts of incidence rates during the 
extension period (changed with amendment 11) and incidence per 100 patient years 
at risk will be presented. For ECG and laboratory  test measurements, vital signs, 
changes from baseline will also be summarized using descriptive methods (mean, 
standard deviation, median, minimum, maximum).
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 42of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Statistical analyses of other variables
Patient s will be included in these analy ses if they areincluded in the safety analy sis 
and have both baseline and post-baseline data available for the variable being 
analyzed. For Time To Clinical Worsening, incidence tables of the overall rate and 
the particular event leading to clinical worsen ing will be presented, together with 
the Kaplan -Meier survival curve. Change in Borg CR 10 Scale or Modified Borg 
Dyspnoea Scale and functional class at each visit will be summarized by frequenc y 
counts. Patients with data on the Borg CR10 Scale and patien ts with data on the 
Modified Borg Dyspnoea Scale will be combined in the statistical analysis. Change 
in 6MWD ,NT pro-BNP , EQ-5D and LPHat each visit will be summarized using 
descriptive methods.
The study  endpoints related to health care resource utiliza tion will be summarized 
using appropriate statistical methods: categorical variables by frequency  tables and 
continuous variables by sample statistics.  It is envisaged that all endpoints will be 
measured either on a semi -continuous scale or have ordered categories, and so 
exploratory  statistical tests will be ANCOVA or the stratified Wilcoxon test, 
depending on the distribution .
Statistical summaries (changed with amendment 11)
It is planned to produce two formal statistical summaries.   The first will be when all 
patients enrolled in the long-term extension at Last Patient First Treatment of the 
PATENT -1 study  have reached Visit 5 and the PATENT -1 study  has been 
unblinded. The second will be at the conclusion of this extension study .Additio nal 
summaries w ill be performed, at least on a y early basis, to monitor long -term safet y.
6.2 Determination of Sample Size
Not applicable
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 43of 75
Final Version 1.0/ 13 Dec 2012/AM D 117.ADVERSE EVENTS
7.1 Contraindications/ Warnings/Precautions /Interactions /Undesirable 
Effects
The potential for drug -drug pharmacod ynamic intera ctions, leading to an 
exaggerated vasodilatation and excess blood pressure drop should alway s be 
considered if patients are treated concomitantly  with other drugs with vasoactive 
properties.
Concomitant treatment with specific or unspecific Phosphodiestera se Inhibitors 
leading to higher production and decreased degradation of cGMP is not allowed 
during the trial (refer to Section 4.5.7 “concomitant therap y”).
Due to possible pharmacody namic interactions, BAY 63-2521 must not be 
administered together with NO donors/nitrates (refer to Section 4.5.7 “concomitant 
therap y”).
Due to possible pharmacokinetic interactions between BAY 63-2521 and strong 
CYP3A4 inhibitors (eg Ketoconazol) concomitant treatment should be applied with 
caution (eg additional blood pressure monitoring). Such drugs may significantly 
increase BAY 63-2521 plasma concentrations. In this context, dose reduction of 
BAY 63-2521 should be considered (eg –0.5 mg tid), in particular if the patient 
suffers a clinical relevant decrease in blood pressure (eg sy stolic blood pressure <90 
mmHg with clinical symptoms). For further information refer to the Investigator 
Brochure.
Antacids like aluminum hydroxide/magnesium hydroxide (eg Maaloxan ®) shou ld 
not be taken simultaneously  with BAY 63-2521, because a negative impact on the 
bioavailability  of the study  drug has been observed (please refer to the Investigator 
Brochure). To avoid such kind of interaction, antacids should be taken 1 hour after 
intake of BAY 63-2521 at the earliest.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 44of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Pre-and co-treatment with Omeprazole led to a decrease in BAY 63-2521 
bioavailability , indicating a lower bioavailability  of BAY 63-2521 in neutral versus 
acidic milieu (for further information refer to the Investigator Brochure).
Preliminary  inspection of trough and peak plasma concentrations of BAY 63-2521 
and BAY 60-4552 (Main BAY 63-2521 metabolite) in a cohort of patient s treated 
with bosentan (n=6) compared to the patient s not treated with bosentan (n=66) 
clearl y indicate a decrease in BAY 63-2521/BAY 60-4552 plasma exposure, most 
probably  due to the known CYP3A4 enzyme-inducing effects of concomitant 
bosentan. However, patient s treated with bosentan profited in about the same 
magnitude in the 6 minute walk test as patient s in the therapy  naïve cohort did (for 
further information refer to the I nvestigator Brochure, trial 12166).
The BAY 63-2521 clearance was increased in smokers compared to non -smokers in 
a previous trial in patients with pulmonary  hypertension (IMP 1 2166; see IB for 
more information). Therefore, patients should report their smoking status to the 
investigator.
Due to the pharmacological mode of action of a guan ylate cyclase stimulator, 
treatment with BAY 63-2521 may unmask existing Pulmonary  Veno-Occlu sive 
disease (PVOD), leading to pulmonary  congestion and subsequent pulmonary 
edema. Given the severity  of the underl ying disease this effect may be life-
threatening. Clinical symptoms of uncovering of a PVOD may occur weeks to 
months after start of treatm ent with BAY 63-2521 . Should signs of pulmonary 
edema occur when BAY 63-2521 is administered, the possibility  of associated 
PVOD should be considered and BAY 63-2521 should be discontinued 
immediately .
The following undesirable effects of the compound have been observed in clinical 
trials: decrease in blood pressure (in healthy  volunteers mainl y diastolic blood 
pressure), postural h ypotension, dizziness, sy ncope, increase in heart rate, nasal 
congestion, feeling hot, headache, d yspepsia, nausea, vomiting, g astritis, flushing, 
and hy perhidrosis (refer to the Investigator Brochure). Most of the undesirable 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 45of 75
Final Version 1.0/ 13 Dec 2012/AM D 11effects are caused b y the vasodilators mode of action of the drug. The effects of the 
compound on smooth muscles may  lead to gastrointestinal sy mptoms (eg d ilation of 
the esophageal sphincter with heartburn, esophagitis and dy sphagia; diarrhea; 
constipation).
In addition, the possibility  of hitherto unforeseen side effects and allergic reactions 
to drugs, which can result in severe damage and even death, must alway s be 
considered.
Any new, relevant information about adverse drug reactions of BAY 63-2521 will 
be given to the patients (verball y and in writing).
Inadvertent overdosing with total daily  BAY 63 -2521 doses of 9 mg (13 and 
32days), 22.5 mg (14 and 15 days), and 25 mg (2 day s) was reported for 5 subjects, 
which was tolerated without any  adverse events (for further information refer to the 
Investigator Brochure).
Overdosage following administration of BAY 63-2521 should be treated as 
clinically  indicate d. There is no known antidote to BAY 63-2521.
Due to the pharmacological profile of BAY 63-2521, cardiovascular effects as 
described in the Investigator Brochure ( Section 5.3.3.3 ) may  be expected in case of 
overdose.
If symptoms develop after the investiga tional drug has been administered, any  
therap y that becomes necessary  has to be guided by  the predominant sy mptoms. 
Patients have to remain under medical supervision until all relevant adverse effects 
have subsided. If adverse events occur, the investigato r has to decide whether or not 
to remove the patient from the trial (refer to Section 4.3). Emergency  drugs and 
equipment has to be available to provide an y treatment, which may  become 
necessary.
In case of overdose, general measures to prevent absorption (eg, gastric lavage, 
activated charcoal) should to be taken.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 46of 75
Final Version 1.0/ 13 Dec 2012/AM D 11Note: To keep the investigators up-to-date regarding any kind of safety  relevant 
information the Development Core Safet y Information (DCSI), which is an 
appendix of the Investigators’ brochure, will be updated at regular intervals during 
the conduct of the trial. New versions of the investigator’s brochure will be made 
available to the investigators without delay .
7.2 Adverse Event Monitoring
Patient s must be carefully monitored for adverse events . Adverse events should be 
assessed in terms of their seriousness, severity , and relationship to the study  drug.
7.3 Adverse Event Definitions
7.3.1 Adverse Event
An adverse event is any untoward medical occurrence in a patient or clinica l 
investigation patient administered with a pharmaceutical product. The adverse event 
does not necessaril y have to have a causal relationship with this treatment. An 
adverse event can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory  finding), symptom, or disease temporall y associated with the 
use of an investigational product, whether or not considered related to the medicinal 
product.
Adverse events associated with the use of a drug in humans, whether or not 
considered dru g related, include the following: 
An adverse event occurring in the course of the use of a drug product in 
professional practice.
An adverse event occurring from an overdose whether accidental or intentional.
An adverse event occurring from drug abuse.
Anadverse event occurring from drug withdrawal. 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 47of 75
Final Version 1.0/ 13 Dec 2012/AM D 11An adverse events where there is a reasonable possibility  that the event occurred 
purely  as a result of the patient s participation in the study  (eg adverse event or 
serious adverse event due to discontinuatio n of anti-hypertensive drugs during 
Wash-Out Phase) must also be reported as an adverse event even if it is not 
related to the investigational product.
The clinical manifestation of any failure of expected pharmacological action is not 
recorded as an adver se event if it is already reflected as a data point captured in the 
electronic CRF (adapted with amendment 11) .  If, however, the event fulfills any  of 
the criteria for a “serious” adverse event, it must be recorded and reported as such.
7.3.2 Serious Adverse E vent
A serious adverse event is any  untoward medical occurrence that at any  dose: 
Results in death.
Is life -threatening.
Requires in -patient hospitalization or prolongation of existing hospitalization.
Results in persistent or significant disability  or in capacit y.
Is a congenital anomal y or birth defect.
Is an important medical event.
Life-threatening : The term “life -threatening” in the definition of “serious” refers to 
an adverse event in which the patient was at risk of death at the time of the event. It
does not refer to an adverse event which hypothetically  might have caused death if 
it were more severe.
Hospitalization : Any adverse event leading to hospitalization or prolongation of 
hospitalization will be considered as Serious, UNLESS at least one of the following 
exceptions are met:
The admission results in a hospital stay  of less than 12 hours.
OR
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 48of 75
Final Version 1.0/ 13 Dec 2012/AM D 11The admission is pre -planned (ie, elective or scheduled surgery  arranged prior to 
the start of the stud y). 
OR
The admission is not associated with an adverse event (eg, social hospitalization 
for purposes of respite care).
However it should be noted that invasive treatment during any hospitalization may 
fulfill the criteria of ‘medicall y important’ and as such may be reportable as a 
serious adverse event dependant on clinical judgment . In addition where local 
regulatory  authorities specificall y require a more stringent definition, the local 
regulation takes precedent.
Any hospitalization required for carry ing out a routine right heart catheterization 
(RHC) procedure for conducting diagnostic invasive hemody namic measurements 
to evaluate a patient’s underly ing disease (without taking into account any clinical 
suspicion or finding with regard to the worsening of the underl ying disease) will not 
be considered as a serious adverse event. In this context, a RHC procedure is 
considered as a procedure and not as an adverse event (changed with amendment 
11).
Disability means a substantial disruption of a person’s ability  to conduct normal 
life’s functions.
Important medical event : Any  adverse event may be considered serious because it 
may jeopardize the patient and may require intervention to prevent another serious 
condition. As guidance for determination of important medical events refer to the 
“WHO Adverse Reactio n Terminology  –Critical Terms List. These terms either 
refer to or might be indicative of a serious disease state. 
Such reported events warrant special attention because of their possible association 
with a serious disease state and may lead to more decisive action than reports on 
other terms. 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 49of 75
Final Version 1.0/ 13 Dec 2012/AM D 117.3.3 Unexpected Adverse Event
An unexpected adverse event is any adverse drug event, the specificity  or severit y 
of which is not consistent with the current Investigator Brochure (refer to Section
8.1. “Development Core Safety  Information” of the Investigator Brochure ). Also, 
reports which add significant information on specificit y or severit y of a known, 
alread y documented adverse event constitute unexpected adverse events. For 
example, an event more specific or more severe than described in the Investigator 
Brochure would be considered “unexpected”. Specific examples would be; (a) acute 
renal failure as a labeled adverse event with a subsequent new report of interstitial 
nephritis and (b) hepatitis with a first report o f fulminant hepatitis.
7.3.4 Relationship of Adverse Event to Investigational Product
The assessment of the relationship of an adverse event to the administration of study  
drug is a clinical decision based on all available information at the time of the 
completion of the case report form.
An assessment of ‘No’ would include:
1. The existence of a clear alternative explanation eg, mechanical bleeding at 
surgical site.
OR
2. Non-Plausibility  eg, the patient is struck by an automobile when there is no 
indication that the drug caused disorientation that may have caused the event; 
cancer developing a few day s after the first drug administration. 
An assessment of ‘Yes’ indicates that there is a reasonable suspicion that the 
adverse event is associate d with the use of the investigational drug.
Factors to be considered in assessing the relationship of the adverse event to study 
drug include: 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 50of 75
Final Version 1.0/ 13 Dec 2012/AM D 11The temporal sequence from drug administration: The event should occur after 
the drug is given.  The length of time from drug exposure to event should be 
evaluated in the clinical context of the event.
Recovery  on discontinuation (de-challenge), recurrence on reintroduction (re-
challenge): Patient ’s response after drug discontinuation (de-challenge) or 
patient s response after drug re-introduction (re-challenge) should be considered 
in the view of the usual clinical course of the event in question.
Underl ying, concomitant, intercurrent diseases: Each report should be evaluated 
in the context of the natural history  andcourse of the disease being treated and 
any other disease the patient may have.
Concomitant medication or treatment: The other drugs the patient is taking or 
the treatment the patient receives should be examined to determine whether any 
of them may  be sus pected to cause the event in question.
The pharmacology  and pharmacokinetics of the test drug: The pharmacokinetic 
properties (absorption, distribution, metabolism and excretion) of the test 
drug(s), coupled with the individual patient ’s pharmacod ynamics should be 
considered.
7.3.5 Severity of the Adverse Event
The following classification should be used:
The severit y of adverse events should be graded as follows:
Mild –usually  transient in nature and generally  not interfering with normal 
activities.
Moderate –sufficiently  discomforting to interfere with normal activities
Severe –prevents normal activities.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 51of 75
Final Version 1.0/ 13 Dec 2012/AM D 117.3.6 Adverse Event Documentation
All adverse events occurring in the period between the patient has signed the 
informed consent and until 30 days after definite stop of study  medication must be 
fully recorded in the patient ’s case record form. However, in case that more than 30 
days after stop of study  medication an adverse event occurred that has been 
considered as related b y the investigator, this needs to be documented too.
Documentation must be supported by  an entry  in the patient ’s file.  A laboratory  test 
abnormality  considered clinically  relevant, eg, causing the patient to withdraw from 
the study , requiring treatment or causing apparent clinical manifestations, or judged 
relevant by the investigator, should be reported as an adverse event.  Each event 
should be described in detail along with start and stop dates, severity , relationship to 
investigational product, action taken and outcome.
7.4 Reporting of Serious Adverse Events/Pregnancy
Serious adverse events (SAEs), including laboratory  test abnormalities fulfilling the 
definition of serious, that occurred in the period between the patient signed the 
informed consent and until 30 daysafter definite stop of study  medication must 
immediately  (within 24 hours of the investigator’s awareness) be reported to the 
person detailed in the study  file. A serious adverse event form must also be 
completed within 24 hours of the investigator’s awareness and forwarded to the 
designated person as detailed in the study  file. For reporting of serious adverse 
events an electronic adverse event as provided in the electronic CRF shall be used. 
If the electronic CRF is not available due to technical problems (eg information 
cannot be entered into the electronic CRF ) serious adverse events need to be 
reported within 24 hours of the investigator’s awareness by using print out forms 
(e.g. via fax). Each serious adverse event must be followed up until resolution or 
stabilization by  submission of updated reports to the designated person.
If Global Pharmacovigilance requests supportive documents in context with a 
serious adverse event report (eg autops y report, hospital report) these documents 
shall be forwarded to the per son detailed in the study  file (eg via fax).
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 52of 75
Final Version 1.0/ 13 Dec 2012/AM D 11The same rules apply to serious adverse events that occurred more than 30 days 
after definite stop of study  medication, if the investigator considers them as related 
to the study  medication.
When required, and according to local law and regulations, serious adverse events 
must be reported to the Ethics Committee and Regulatory  Authorities.
Pregnancy  occurring during a clinical investigation, although not considered a 
serious adverse event, must be reported to Bayer within the same timelines as a 
serious adverse event on a Pregnancy  Monitoring Form. The outcome of a 
pregnancy  should be followed up carefull y and any abnormal outcome of the 
mother or the child should be reported. This also applies to pregnancies following 
the administration of the investigational product to the father prior to sexual 
intercourse.
7.5 Reporting of Safety Related Events of Special Interest
For this trial the following safet y related event of special interest ha sbeen defined:
Syncope
Any syncope has to be reported as “important medical event” (see section 7.3.2 ) and 
therefore as Serious Adverse Event (SAE) to the sponsor within 24 hours of 
becoming aware of the event.
8.USE OF  DATA AND PUBLICA TION
All data and results and all intellectual propert y rights in the data and results derived 
from the study  willbe the propert y of the sponsor, who may utilize the data in 
various ways, such as for submission to government regulatory  authorities or 
disclosure to other investigators. The investigator, whilst free to utilize data derived 
from the study  for scientific purposes, must discuss any publication with the 
sponsor prior to release and obtain written consent of the sponsor on the intended 
publication. The sponsor recognizes the right of the investigator to publish the 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 53of 75
Final Version 1.0/ 13 Dec 2012/AM D 11results upon completion of the study . Howev er, the investigator must send a draft 
manuscript of the publication or abstract to the sponsor thirty  days in advance of 
submission in order to obtain approval prior to submission of the final version for 
publication. This will be reviewed promptly  and approval will not be withheld 
unreasonabl y. In case of a difference of opinion between the sponsor and the 
investigator(s), the contents of the publication will be discussed in order to find a 
solution which satisfies both parties.
9.REFEREN CES
Investigator Brochure: BAY 63-2521
American College of Chest Phy sicians. Diagnosis and Management of Pulmonary  
Arterial Hy pertension: ACCP Evidence -Based Clinical Practice Guidelines. Chest 
2004; 126; 7 -10s
American Heart Association. Recommendations for Blood Pressure Measurement in 
Humans and Experimental Animals. Hypertension 2005;45;142 -161
American Thoracic Society . ATS Statement: Guidelines for Six-Minute Walk Test. 
American Journal of Respiratory  and Critical Care Medicine 2002; Vol 166. pp 11 1-
117
10.APPENDICES
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 54of 75
Final Version 1.0/ 13 Dec 2012/AMD 1110.1 Study Flow Chart
Tabular Schedule of Study Procedures
Study Phase PATENT -1PATENT -2
Treatment Phase (Duration until BAY 63 -2521 receives official approval and will be commercially available)
Safety -Follow -Up Phase 
                          (30 days + 5 )
Titration Phase (8 weeks) Main -Study Phase
Blinding of study medicationBlinded 
treatmentBlinded with respect to the BAY 63 -2521 dose Unblinded
VisitV 6 of 
PATENT -1V 1gV 2 V 3 V 4 V 5 V6V7-V n
(every 90 days)Termi nation 
VisitcSafety -Follow 
Up-Visit 
Day -1 0 14±2 28±2 42±2 56±2 84±2174±14
Vn+14- 30 + 5
Week - 0 2 4 6 8 12 24-n - -
In-patient hospitalization -optional XaXb- - - - - - -
Informed consent X
Patient’s Weight X X X X X
Concomitant Medication X X X X X X X X X
Collection of smoking statushX X X X X X
Physical examination X X X X X
Blood pressure, heart rate X X X X X X X X X X
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 55of 75
Final Version 1.0/ 13 Dec 2012/AMD 11Tabular Schedule of Study Procedures
Study Phase PATENT -1PATENT -2
Treatment Phase (Duration until BAY 63 -2521 receives official approval and will be commercially available)
Safety -Follow -Up Phase 
                          (30 days + 5 )
Titration Phase (8 weeks) Main -Study Phase
Blinding of study medicationBlinded 
treatmentBlinded with respect to the BAY 63 -2521 dose Unblinded
VisitV 6 of 
PATENT -1V 1gV 2 V 3 V 4 V 5 V6V7-V n
(every 90 days)Termi nation 
VisitcSafety -Follow 
Up-Visit 
Day -1 0 14±2 28±2 42±2 56±2 84±2174±14
Vn+14- 30 + 5
Week - 0 2 4 6 8 12 24-n - -
Blood gas analysis X X
WHO functional classdX X X X X X X X
6 MWD TestdX X X X X X X X
Borg CR 10 Scaledor Modified 
Borg ScalefX X X X X X
EQ-5D Questionnaire X X X
LPH Questionnaire X X
Use of healthcare resources X X X X X X
Standard lab. blood sampling X X X X X X
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 56of 75
Final Version 1.0/ 13 Dec 2012/AMD 11Tabular Schedule of Study Procedures
Study Phase PATENT -1PATENT -2
Treatment Phase (Duration until BAY 63 -2521 receives official approval and will be commercially available)
Safety -Follow -Up Phase 
                          (30 days + 5 )
Titration Phase (8 weeks) Main -Study Phase
Blinding of study medicationBlinded 
treatmentBlinded with respect to the BAY 63 -2521 dose Unblinded
VisitV 6 of 
PATENT -1V 1gV 2 V 3 V 4 V 5 V6V7-V n
(every 90 days)Termi nation 
VisitcSafety -Follow 
Up-Visit 
Day -1 0 14±2 28±2 42±2 56±2 84±2174±14
Vn+14- 30 + 5
Week - 0 2 4 6 8 12 24-n - -
NT-pro BNP X X X X X X
PK blood sampling X X X
12-lead electrocardiogram X X X X X X X
Pregnancy test (if applicable) XeX XiXi
Dispense study medication X X X X X X X
Drug accountability X X X X X X X X
Collection of patient Diary X X X X
Event of special interest evaluation X X X X X X X X X
Adverse event reporting XfXfX X X X X X X X
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 57of 75
Final Version 1.0/ 13 Dec 2012/AMD 11Flowchart updated (last with amendment 11)
Indexes:
aAccording to hospital routine, patients may  be hospitalized for one day  after the performance o f invasive hemody namic measurements .
bPatients will be discharged if there is no medical objection. Blood pressure monitoring and heart rate arethe main hemody namic safet y 
parameters that need to be considered .
cA Termination Visit will only  be perform ed in case of premature stop of study  medication or if the sponsor announces the official end of the 
study . In such case, generally  the same measurements and procedures should be performed as at Main -Study  Visits (V7–Vn). In particular, 
every  effort shou ld be made to perform the 6MWD Test. Deviations, particularl y from the scheduled points in time need to be documented in 
the electronic CRF .
dDuring the Titration Phase t hese test have to be performed b y a second person (for WHO functional class assessme nt a second phy sician) 
who is not involved in the process of study  drug titration and is unaware of the immediate reaction of the patient’s blood pr essure and heart 
rate after dosing. This person will record the test results on a separate work sheet and a different person (could be the same person as involved 
in titration) will enter them into the electronic CRF
For consistency  reason, patients who were enrolled in trial 1293 4 before approval o f protocol amendment 4 in their country  must use the 
“Modified B org Dy spnoea Scale” throughout the main and the extension study    (for further details see section 4.6.4 ).
eAt Visit 6 of PATENT -1 a urine ( if the patient will participate in the extension study ) and a serum pregnancy  test sh ould be performed . 
Female patients with childbearing potential can be enrolled into the extension study  based on the results of the urine test
fAdverse events that occur before intake of first dose of PATENT -2 medication will be allocated to PATENT -1.
gIt is not permitted to include a patient into the extension study  on the same day  of V6 of PATENT -1 study  (applies even if Visit 6 
investigations were performed at two consecutive day s).
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 58of 75
Final Version 1.0/ 13 Dec 2012/AMD 11hPatients will be asked if their smoking habits has changed since the previous visit and the results will be recorded in the electronic CRF
i Test to be done locally
Visit Details
Day Day 0
Visit 1 First cycle of 
measurementsc
First study  medication 
dose intakeSecond cycle of 
measurementsc
Second study  medication 
dose intake
Order of 
proceduresStarting point of 
proceduresTime interval (h)00
>-01
<0000
00c00
>02
<0300
>-01
<0000
00c00
>02
<03
Blood pressure, heart ratebX X
12-lead ECGa,bX
Pharmacokinetic blood samplebX
Administrati on of BAY 63-2521bX X
Blood pressure, heart ratebX X
Discharge from ward X
aSingle ECG
bThe point in time when the respective procedures are performed will be documented in the case report form.
cThe respective single daily  doses of study  medication should be taken 6 -8hours apart.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 59of 75
Final Version 1.0/ 13 Dec 2012/AMD 11Ambulatory Visits 
Visit 2 –Visit 5Cycleof measurements
Order of 
proceduresStarting point of 
proceduresTime interval (h)00
>-01
<0000
0000
>02
<0300
>04
<05
Blood pressure, heart ratecX
12-lead ECGa,cX
Pharmacokinetic blood samplec, dX
Administration of BAY 63-2521c X
Blood pressure, heart ratecX
6 MW D testb,cX
Borg CR 10 Scale (or Modified Borg 
Dyspnoea Scale)b,cX
aSingle ECG
bDuring the Titration Phase these test have to be performed b y a second person who is not involved in the process of stud y drug titra tion and is 
unaware of the immediate reaction of the patient’s blood pressure and heart rate after dosing. This person wi ll record the test results on a 
separate work sheet and a different person (could be the same person as involved in titration) will enter them into the electronic CRF.
cThe point in time when the respective procedures are performed will be documented in t he case report form.
dPharmacokinetic blood sample will only  be collected at Visit 5
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 60of 75
Final Version 1.0/ 13 Dec 2012/AMD 11Ambulatory visits V6 Cycle of measurements
Order of 
proceduresStarting point of 
proceduresTime interval (h)00
>-01
<0000
0000
>02
<0300
>04
<05
Blood pressur e, heart rate bX
12-lead ECG a, bX
Administration of BAY 63-2521 bX
Blood pressure, heart rate bX
6 MW D test bX
Borg CR 10 Scale (or Modified Borg 
Dyspnoea Scale) bX
aSingle ECG (updated with amendment 11)
bThe point in time when the respective procedures are performed will be documented in the case report form.
aThe point in time when the respective procedures are performed will be documented in the case report form
(updated with amendment 11) .Ambulatory visits V7 –Vn, Termination Visit Cycle of 
measurements
Order of 
proceduresStarting point of 
proceduresTime interval (h)00
>-01
<0000
0000
>00
<01
Blood pressure, heart rateaX
Administration of BAY 63-2521aX
6 MW D testaX
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 61of 75
Final Version 1 .0/ 13 Dec 2012/AMD 1110.2 Pharmac okinetic Sampling
The number of samples taken for the assessment of pharmacokinetics 
has been optimized to take the minimum amount of blood.
PK samples will be anal yzed under the responsibility  of the Institute of 
Clinical Pharmacology , BAYER AG, Wuppertal , German y.
Visit 1
Point in time : -01-00hours before administration of the second dose of 
BAY 63-2521 (Day  1)
V 5
At this study  visit the patients should present themselves to the hospital 
without taking the morning dose of BAY 63-2521. During the visit the 
pharmacokinetic sample should alway s be taken at trough before 
administration of the morning dose of stud y medication.
Point in time: -01-00 hours before administration of BAY 63-2521 
morning dose
Sample collection, processing and storage
The blood sam ples will be collected in specific tubes which will be 
provided b y the central laboratory. Further details on collection, 
labeling, storage and shipping of samples are provided in a separate 
laboratory  manual.
At the latest at the end of the study  when all planned anal yses are 
completed, all PK samples will be destro yed.
10.3 Blood Gas Analysis
Blood gases are to be obtained from the arterial blood or from 
arterialized capillary  blood. All samples should be obtained with the 
patient resting in a sitting or supin eposition for at least 10 min. I f 
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 62of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11possible no supplementary  oxygen should be given during the resting 
period and while blood samples are drawn. If the patient requires 
oxygen, care should be taken that all samples are drawn with the same 
flow of ox ygen th roughout the study  whenever possible. Printouts from 
the analyzerhave to be stored in the patient file and the measured values 
have to be transferred into the electronic CRF.
Blood gas measurement
Actual time
Date
SaO2 (%)
PaO2 (mmHg)
PaCO 2 (mmHg)
Supplemental oxygen “Yes” or “No”
If “Yes”,amount of supplemental O 2(l/min)
10.4 6 Min Walking Distance (6MWD) Test
The 6MWD Test must be performed in accordance with the American 
Thoracic Societ y Guideline ( American Thoracic Society . ATS Statement: 
Guidelines for Six-Minute Walk Test. American Journal of Respiratory  
and Critical Care Medicine 2002; Vol 166. pp 11 1-117)
According to the guideline, the 6MWD Test should be carried out 
indoors, along a long, flat, straight, enclosed corridor with hard surface 
that is seldom traveled. The walking course should be preferabl y 30 m in 
length but not less than 25 meters (longer walking courses should be 
shorten edto 30 m). The length of the corridor and turnaround points 
should be marked.
Patients will be instructed to walk alone, not run, from one end to the 
other end of the walking course, at their own pace, while attempting to 
cover as much ground as possible in 6 min.
During the walk, patients are allowed to stop, lean against the wall and 
rest, but should resume walking as soon as they  feel able to do so.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 63of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11A “warm -up” period before the test should not be performed. The 
patients should sit at rest in a chair, located near the starting position, for 
at least 10 minutes before the test starts.
Investigators should not walk with the patients. Moreover, only 
standardized phrases for encouragement must be used during the test. To 
allow reproducibility , standardized phrases should be used every minute 
according to the following pattern:
After the first minute, tell the patient the following (in even tones): 
“You are doing well. You have 5 minutes to go.”
When the timer shows 4 minutes remaining, tell the patient the 
following: “Keep up the good work. You have 4 minutes to go.”
When the timer shows 3 minutes remaining, tell the patient the 
following: “You are doing well. You are halfway  done.”
When the timer shows 2 minutes remaining, tell the patient the 
following: “Keep up the good work. You have only 2 minutes left.”
When the timer shows only 1 minute remaining, tell the patient: 
“You are doing well. You have onl y 1 minute to go.”
To reduce the variability of the 6MWD Tests, it is of utmost importance 
that the eligibility -test, the baseline -test and all following tests are 
performed under the same co nditions (trunc ated with amendment 11) :
Patients, who used walking aids alread y at the eligibility -test 
and the baseline -test (eg cane, walker), need to use the same 
walking aids at every  subsequent 6MWD Test.
For quality  reasons, the inhalation of supplem ental oxygen and the use 
of walking aids during the 6MWD Tests must be documented in the 
CRF.
In case that a patient has never performed a 6MWD Test, a 
familiarization test should be performed during the Pre-Treatment Phase. 
To avoid any interactions, it is not permitted to perform the 
familiarization test on the same day  as the eligibility  6MWD Test.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 64of 75
Final Version 1 .0/ 13 Dec 2012/AMD 1110.5 Borg CR 10 Scale®or Modified Borg Dyspnoea Scale 
In context with 12934 protocol amendment 4 the “Modified Borg 
Dyspnoea Scale” was replaced by  the Borg CR 10 Scale®. For 
consistency  reason, patients who were enrolled before approval of 12934  
protocol amendment 4 in their country  must use the “Modified Borg 
Dyspnoea Scale” throughout the main and the extension study .
The Borg CR 10 Scale or the Modified Borg Dyspnoea Scale will 
alway s be measured in conjunction with the 6MWD Test.
The Borg CR 10 Scale or the Modified Borg Dy spnoea Scale will be 
explained to the patients before starting the 6MWD Test ( questionnaires 
and instructions will be provided in local l anguage). Patients will be 
asked to rank their exertion at the end of the 6MWD Test. If a patient 
has problems to understand the principles of rating, an attempt should be 
made to explain the principles in a neutral and unpersuasive manner.
The test result will be entered on same work sheet as the 6MWD Test 
result Later on the results will be transferred into the electronic CRF.
10.5.1 Borg CR 10 scale and test instructions
 
 
 
 
 
 
 
 
 
 
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 65of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11 
 
 
 
 
 
 
 
CCI
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 66of 75
Final Version 1 .0/ 13 Dec 2012/AMD 1110.5.2 Modified Borg Dyspnoea Scale
 
CCI
CCI
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 67of 75
Final Version 1 .0/ 13 Dec 2012/AMD 1110.6 WHO functional class
The patient’s functional class will be determined by  using the WHO 
classification (Class I -IV / refer to American College of Chest 
Physicians. Diagnosis and Management of Pulmonary  Arterial 
Hypertension: ACCP Evidence -Based Clinical Practice Guidelines. 
Chest 2004; 126; 7-10s ):
I: Patients with PH but without resulting limitation of physical activit y. 
Ordinary  physical activity  does not cause undue dyspnoea or fatigue, 
chest pain, or near s yncope.
II: Patients with PH resulting in slight limitation of physical activit y. 
They  are comfortable at rest. Ordinary  physical activity  causes undue 
dyspnoea or fatigue, chest pain, or near s yncope.
III: Patients with PH resulting in marked limitation of physical activity . 
They  are comfortable at rest. Less than ordinary activity  causes undue 
dyspnoea or fatigue, chest pain, or near s yncope.
IV: Patients with PH with inability  to carry  out any  physical activity  
without sy mptoms. These patients manifest signs of right- heart failure. 
Dyspnoea and/or fatigue may  even be present at rest. Discomfort is 
increased b y any physical activity .
10.7 EQ-5D
 
 
 The EQ -5D is a self -report questionnaire and needs to 
CCI
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 68of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11be completed b y the patient (questionnaires will be provided in local 
language). However, if the patient has problems c ompleting the 
questionnaire, an attempt should be made to explain the questions in a 
neutral and unpersuasive manner.
After the patient has filled in the questionnaire, the questionnaire is 
transferred to the study  personnel, who will enter the content into the 
electronic CRF.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 69of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 70of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 71of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 72of 75
Final Version 1 .0/ 13 Dec 2012/AMD 1110.8 Living w ith Pulmonary Hypertension questionnaire (LPH)
 
The L PHis a self -report questionnaire and needs to be completed b y the 
patient (questionnaires will be provided in local language) . However, if 
the patient has problems completing the questionnaire, an attempt should 
be made to explain the questions in a neutral and unpersuasive manner.
After the patient has filled in the questionnaire, the questionnaire is 
transferred to the study personnel, who will enter the content into the
electronic CRF.
 
 
 
CCI
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 73of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11
CCI
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 74of 75
Final Version 1 .0/ 13 Dec 2012/AMD 1110.9 Role of the Steering Committee (SC)
The Steering Committee has the overall scientific responsibility  of the 
study . It will guide the trial in all aspects of safet y and efficacy  and has 
to assure that all relevant information coming from the sponsor (e.g. 
from the Global Pharmacovigilance department), from other study  
committees (e.g. from the Data Monitoring Committee) and from the 
investigators will thoroughl y be review ed and all relevant decisions with 
regard to the conduct will be taken in due time. In particular the Steering 
committee has the following responsibilities:
 Primary  responsibility  for designing the stud y
 Primary  responsibility  for the content of protocol a mendments
 To ensure a scientificall y sound and safe conduct of the study
 To decide on Data Monitoring Committee recommendations 
together with the sponsor
 Primary  responsibility  for the final study  report
10.10 Role of the Data Monitoring Committee (DMC)
It is th e main responsibility  of the Data Monitoring Committee (DMC) 
to protect t he safety  of the patients participating in the BAY 63 -2521 
phase III program. In this context, the DMC will regularl y review 
accumulating study  data with the responsibility  to provide an 
independent recommendation on the advisability  of continuing the stud y 
as planned.
The DMC will conduct its reviews based on unblinded data summaries. 
During the course of the trial the DMC and the SC should closely  
interact and alert each other in order to assess all safet y relevant 
information. The DMC should also closely interact with the sponsor´s 
Global Pharmacovigilance department.
Integrated Protocol /Study number BAY 63 -2521/12935/ Page 75of 75
Final Version 1 .0/ 13 Dec 2012/AMD 11In case of unacceptable safet y profile, the DMC can recommend to stop 
the trial. However, the final decision will be made by  the SC together 
with the sponsor.
DMC will stop when all patients are on open label dose of Riociguat
(changed with amendment 11) .
For further details refer to the DM C Charter.